Hypertension Series
Secondary Hypertension: When High Blood Pressure Has a Treatable Driver
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history, genetic factors, and concurrent conditions. Always consult qualified healthcare providers for medical decisions and before making changes to your care. Never delay seeking medical care based on content you have read. If you are experiencing a medical emergency, seek immediate medical attention.
This article is education to help you partner with your clinicians; it is not a substitute for individualized medical advice. All treatment decisions should involve your healthcare team.
In Brief
Most high blood pressure is primary (essential) hypertension — it develops gradually from the mix of genetics, aging, weight, salt, sleep, and the other factors Article 4 covered. But roughly 5–10% of adults with hypertension — and 20–30% of those with resistant hypertension — have an identifiable underlying driver: sleep apnea, a hormone-producing tumor, kidney disease, a narrowed kidney artery, a structural problem with the aorta, or a medication that’s pushing pressure up. That’s secondary hypertension.
When the driver is found and treated, blood pressure often becomes easier to control — sometimes dramatically. The question isn’t “should everyone be tested for every secondary cause?” — that would be impractical and produce mostly false results. The question is “does this person’s blood pressure pattern fit ordinary primary hypertension, or does it suggest something else?” This article covers the patterns clinicians look for, the most common drivers, and what evaluation actually looks like.
Article 4 covered the everyday factors that push blood pressure up — weight, salt, alcohol, tobacco, stress, sleep, and so on. For most people, those factors and the underlying biology Article 3 described are enough to explain why blood pressure is elevated.
But some people have an additional, identifiable driver behind their hypertension — and finding it can change everything. A blood pressure that has been frustratingly resistant to three or four medications may improve substantially when sleep apnea is treated. A young person with severe hypertension may turn out to have primary aldosteronism (a treatable hormone problem). Stopping an over-the-counter decongestant or NSAID can sometimes restore control. The trick is recognizing when blood pressure is behaving in a way that should make you and your clinician look more carefully.
One important point up front: primary and secondary hypertension are not always separate. Many people have primary hypertension with a secondary contributor layered on top. In that situation, secondary contributors often coexist with — and amplify — the biology already pushing blood pressure up (obesity plus sleep apnea, chronic kidney disease plus salt sensitivity, primary aldosteronism plus other resistant features). Treating the secondary driver may not eliminate hypertension entirely, but it can meaningfully improve control and lower long-term cardiovascular risk. (1)
Primary vs Secondary Hypertension: The Practical Difference
| Feature | Primary Hypertension | Secondary Hypertension |
| How it develops | Gradually, from many factors | Driven by one identifiable cause |
| Typical pattern | Slowly progressive over years | Abrupt onset, severe, episodic, or resistant to medication |
| Treatment response | Multiple pathways; lifelong management | May improve substantially with targeted therapy |
| Reversibility | No | Sometimes partial; occasionally near-complete |
The prevalence figures above — secondary hypertension in roughly 5–10% of adult hypertension overall, 20–30% in resistant hypertension — explain where recognition matters most: in patients whose blood pressure doesn’t behave like ordinary primary hypertension. (1,2) The likelihood also rises in younger patients: in adolescents and young adults with hypertension, secondary causes are far more common than in older adults.
Why recognition matters: some secondary causes carry cardiovascular and organ-damage risks beyond what the blood pressure number alone would predict. Primary aldosteronism, for example, is associated with substantially higher rates of stroke, heart failure, atrial fibrillation, and coronary disease compared to people with primary hypertension at the same blood pressure level. (3,4) Other secondary causes allow treatment to be directed at the underlying biology rather than adding more and more blood pressure medications.
One important caveat about reversibility: even when a secondary driver is found and treated, long-standing damage to blood vessels and the heart may prevent blood pressure from fully normalizing. Cure of the driver and cure of the hypertension are not always the same thing — particularly when the secondary cause went undiagnosed for years.
When to Suspect Secondary Hypertension
Secondary causes are not evaluated in everyone with high blood pressure. The goal is to recognize patterns that justify a closer look. (1,2,5)
Patterns that should raise suspicion:
- Early onset — hypertension before age 30, especially without obesity or strong family history. In children, adolescents, and young adults, secondary causes are much more likely than in older adults, and evaluation is often pursued more readily.
- Abrupt onset — blood pressure that suddenly appears or suddenly worsens after being stable
- Resistant hypertension — pressure uncontrolled on three or more blood pressure medications of different classes (typically including a diuretic), or requiring four or more medications for control (5,6)
- Severe hypertension or hypertensive crises without an obvious trigger
- Suggestive symptoms or exam findings, such as:
- Loud snoring, witnessed pauses in breathing, daytime sleepiness (sleep apnea) (7)
- Spontaneous or diuretic-associated low potassium (primary aldosteronism) — though potassium is often normal (8,9)
- Episodic headache, sweating, palpitations, and pressure spikes (pheochromocytoma) (10)
- Kidney dysfunction, protein in the urine, or abnormal urinalysis (kidney disease) (2,11)
- Higher blood pressure in the arms than the legs, or weak femoral pulses (aortic coarctation) (12)
Severity alone is not diagnostic. Severe hypertension by itself doesn’t prove a secondary cause is present, but it raises suspicion when combined with other suggestive features. The same is true for resistance: not every “resistant” case is biologically resistant (more on this below).
No single feature settles the question. Clinicians put the whole picture together — age of onset, blood pressure pattern, symptoms, exam findings, lab results, and response to medication — and ask whether it fits ordinary primary hypertension or points elsewhere.
“Apparent” vs True Resistant Hypertension
Before considering secondary causes in someone whose blood pressure isn’t responding to medication, it’s worth checking whether the resistance is real. Apparent resistant hypertension — blood pressure that looks uncontrolled — is sometimes caused by things other than true biological resistance:
- Measurement problems — wrong cuff size, talking during measurement, no rest period, only office readings (where white-coat effect inflates the number)
- Medication adherence — missed doses, taking medications incorrectly, or not being able to afford refills
- White-coat effect — pressure that’s high in the office but normal at home (covered in Article 2)
- Volume / salt issues — very high sodium intake or inadequate diuretic dosing
- Interfering substances — NSAIDs, decongestants, alcohol, or other medications and substances raising pressure (Article 4)
Sorting through these is often the first step before extensive testing for secondary causes. Sometimes “resistant” hypertension turns out to be a measurement problem or an over-the-counter ibuprofen habit. (5)
The Most Common Secondary Drivers
In real-world practice, most secondary hypertension falls into a small number of categories:
- Obstructive sleep apnea
- Primary aldosteronism
- Kidney disease (the kidney tissue itself, or the arteries feeding the kidneys)
- Medications and substances
Less common but high-impact causes — pheochromocytoma, Cushing syndrome, aortic coarctation — matter because missing them carries disproportionate risk even though they are rare.
Obstructive Sleep Apnea (OSA)
OSA is one of the most common secondary contributors to hypertension, and it is especially common in resistant hypertension. (7,13)
Why OSA raises blood pressure: repeated airway obstruction during sleep causes brief drops in oxygen and brief arousals, each triggering surges in fight-or-flight nervous system activity. Over time, this shifts baseline nerve and vascular tone upward, contributing to sustained daytime hypertension. The condition also disrupts the normal nighttime drop in blood pressure (called “dipping”) — and loss of dipping is itself associated with higher cardiovascular risk.
When suspicion should be high:
- Loud, habitual snoring or witnessed pauses in breathing
- Excessive daytime sleepiness or feeling unrefreshed after sleep
- Resistant hypertension or non-dipping pattern on 24-hour monitoring
- Normal body weight does not rule out OSA — airway anatomy matters too
Treatment and expectations: CPAP (continuous positive airway pressure) is the cornerstone of treatment for moderate-to-severe OSA. Meta-analyses show modest average blood pressure reductions (typically 2–7 mmHg systolic), with larger effects in people with severe OSA and good CPAP adherence. (14) An important honesty point: large randomized trials, including the SAVE trial, have not shown that CPAP reduces hard cardiovascular events (heart attack, stroke, cardiovascular death) in patients with moderate-to-severe OSA and established cardiovascular disease compared with usual care. (15) CPAP does meaningfully improve sleep quality, daytime function, and blood pressure, and untreated severe OSA carries serious risks beyond blood pressure — heart attack, stroke, atrial fibrillation, daytime accidents from sleepiness, increased mortality. But the patient education claim that “CPAP prevents heart attacks” is not supported by current trial evidence.
Specialist involvement: Sleep medicine. Referral threshold is generally lower for resistant hypertension or a strong symptom pattern.
Primary Aldosteronism (PA)
Primary aldosteronism is far more common than once recognized. Recent data suggest it affects roughly 5–14% of people with hypertension in primary care and 20–30% in referral clinics — yet up to 95% of cases remain undiagnosed, often for many years. (8,9)
Why it matters: aldosterone excess causes more cardiovascular harm than blood pressure alone would predict. Compared with people who have primary hypertension at the same blood pressure level, patients with PA have approximately 2.5 times the risk of stroke, 3.5 times the risk of atrial fibrillation, twice the risk of heart failure, and a meaningfully elevated risk of coronary artery disease. (3,4) PA-specific treatment (mineralocorticoid receptor blockers or, in selected cases, surgery) reduces these risks beyond what comes from blood pressure control alone.
A critical point: normal potassium does NOT rule out primary aldosteronism. Many — probably most — patients with PA have entirely normal potassium levels. The older textbook teaching that PA always shows up with low potassium is wrong and has contributed to massive underdiagnosis. (8,9)
When to consider PA:
- Resistant hypertension (5,6)
- Hypertension with low potassium, whether on its own or after a diuretic
- An incidental adrenal nodule found on imaging in someone with hypertension
- Family history of early stroke or severe hypertension
The 2025 Endocrine Society guideline goes further than earlier guidance: when resources, expertise, and capacity allow, it suggests screening all patients with hypertension for PA at least once, using a blood test that measures aldosterone and renin levels and calculates their ratio. (9) This is a conditional recommendation (suggested rather than strongly recommended) reflecting that the underlying evidence is moderate rather than definitive — but it represents a significant shift from prior guidelines that limited screening to higher-risk patients. The 2024 ESC guideline and the 2025 AHA/ACC guideline also move toward broader screening. (16,17) Whether broader screening is implemented in any given setting depends on local laboratory resources and clinical workflow.
Screening (in concept): the aldosterone-to-renin ratio (ARR) is the standard screening test. Interpretation is sensitive to potassium status, salt intake, and many blood pressure medications, so timing of testing and what medications a patient is taking matter. False positives and false negatives both happen, so results are interpreted in the context of the full clinical picture rather than on the number alone. (9,18)
Treatment:
- Unilateral PA (one adrenal gland producing too much aldosterone): surgical removal of that gland often substantially improves blood pressure and reduces medication burden in well-selected patients. (19)
- Bilateral PA or non-surgical candidates: mineralocorticoid receptor blockers (spironolactone or eplerenone) are the foundation of treatment. (9)
Specialist involvement: Endocrinology — often working with hypertension specialists or nephrologists.
Kidney-Related Secondary Hypertension
The kidneys both cause and suffer from high blood pressure. Two main categories:
Chronic kidney disease (CKD) — affecting the kidney tissue itself. Hypertension and CKD reinforce each other over time: high pressure damages the kidneys, and damaged kidneys raise pressure. Screening starts with basic kidney function tests and urine analysis. Blood pressure targets and treatment in CKD follow dedicated guidelines. (11,20)
Renovascular disease — narrowing of the arteries that feed the kidneys, most often from atherosclerosis (in older patients) or fibromuscular dysplasia (FMD, a non-atherosclerotic blood vessel condition that classically affects younger women and can be associated with severe or resistant hypertension that responds well to treatment). Severe narrowing of any cause can drive resistant hypertension and kidney dysfunction.
An important distinction: many people have visible narrowing of the renal arteries on imaging that is not actually driving their hypertension. Anatomy alone doesn’t determine whether revascularization (opening the artery with a stent or surgery) will help. Large randomized trials have shown that routine stenting of atherosclerotic renal artery narrowing does not improve outcomes over optimized medical therapy for most patients. (21) Current guidance reserves revascularization for selected high-risk clinical situations rather than treating every narrowing that imaging finds. (22)
Specialist involvement: Nephrology, cardiology, and vascular teams as appropriate.
Pheochromocytoma and Paraganglioma
These are tumors that produce excess catecholamines (adrenaline-like hormones). They are rare — far less common than their visibility in medical education suggests — but they can be dangerous if missed.
Classic features: the textbook presentation is episodic headache, sweating, palpitations, and severe blood pressure spikes. Symptoms often come in attacks because tumor hormone release tends to fluctuate. Between attacks, blood pressure and how the person feels can be entirely normal. (10)
Evaluation relies on blood or urine testing for the breakdown products of these hormones (plasma or urinary metanephrines), followed by imaging if testing is positive. Surgery — after careful preparation with blood pressure medications — is the definitive treatment.
Specialist involvement: Endocrinology and endocrine surgery.
Cushing Syndrome and Other Endocrine Causes
Cushing syndrome refers to the body being exposed to too much cortisol. The most common form by far is from medication — long-term use of oral or injected steroids like prednisone for asthma, autoimmune disease, or organ transplant. Endogenous Cushing syndrome (caused by a tumor producing cortisol or ACTH) is uncommon. Either form can cause hypertension. Suspicious features include weight gain in a typical pattern (round face, fat over the upper back, abdominal weight gain with relatively thin arms and legs), easy bruising, purple stretch marks, muscle weakness in the upper legs and arms, elevated blood sugar, and changes in mood or sleep. (2)
Thyroid disease (over- or under-active) and hyperparathyroidism (too much parathyroid hormone) can also contribute to hypertension and are tested for when clinical or lab findings suggest them.
Aortic Coarctation
A narrowing of the aorta — the main artery leaving the heart — that is present from birth but may not be diagnosed until adolescence or adulthood. It causes high blood pressure in the upper body (arms, head) and lower pressure in the legs.
Clues: notably higher arm than leg blood pressure, weak or delayed femoral pulses, a heart murmur, or leg fatigue with exercise. (12)
Intervention — surgical repair or stenting — is considered when there’s a significant pressure gradient or related complications. Even after successful repair, lifelong follow-up is needed; some people retain elevated cardiovascular risk despite anatomic correction. (12)
Specialist involvement: Cardiologists who specialize in adult congenital heart disease.
Medications and Substances
This is one of the most common — and most overlooked — contributors to difficult-to-control blood pressure. A careful review of every medication and substance a patient is taking should always come before extensive testing for rarer secondary causes.
Over-the-counter and lifestyle culprits (covered more fully in Article 4):
- NSAIDs (ibuprofen, naproxen, others)
- Decongestants (pseudoephedrine, phenylephrine) in cold and allergy products
- Estrogen-containing contraceptives and some hormone therapies
- Steroids (prednisone and similar) and some immune-suppressing medications
- Certain antidepressants (especially SNRIs and MAOIs)
- Prescribed and illicit stimulants (including ADHD medications, cocaine, methamphetamine, MDMA)
- Heavy alcohol
- Over-the-counter supplements, energy products, and performance-enhancing substances — sometimes substantially
Prescription medications used for chronic conditions can also raise blood pressure. These often get missed because the medication is essential for another serious condition and isn’t immediately reviewed as a hypertension cause:
- Calcineurin inhibitors (tacrolimus, cyclosporine) — used in transplant recipients and some autoimmune conditions
- Erythropoiesis-stimulating agents (epoetin alfa, darbepoetin) — used for anemia in chronic kidney disease and chemotherapy
- VEGF inhibitors and tyrosine kinase inhibitors (bevacizumab, sunitinib, others) — used in cancer treatment
- Some chemotherapy regimens and immunotherapies
- Some immune-modulating medications used in autoimmune disease
If you take any medication for a chronic medical condition and have developed new or worsening hypertension, it’s worth asking your clinician whether the medication could be contributing. Stopping a necessary medication is rarely the answer, but knowing it’s part of the picture changes how the blood pressure is managed.
Bringing a complete list of everything you take — prescriptions, every over-the-counter product, supplements, herbal preparations — to blood pressure appointments is one of the highest-yield things you can do. (2,5)
Why Testing Can Be Tricky
Secondary hypertension testing is harder than it looks. Three reasons:
Hormones fluctuate normally. Aldosterone, renin, cortisol, and catecholamines all vary by time of day, body position, recent eating, stress level, and sodium status. A single test result is a snapshot of biology that is constantly in motion.
Blood pressure medications change hormone levels. Many common antihypertensive drugs (especially mineralocorticoid receptor blockers, beta blockers, and diuretics) directly affect renin or aldosterone levels. This means a test result on medication may not reflect what the result would be off medication.
Stress and conditions affect testing. Plasma metanephrines (used to test for pheochromocytoma) can be falsely elevated by physical stress, anxiety, posture during the blood draw, or inadequate rest before sampling. Mild elevations are often re-tested under better-controlled conditions before moving to imaging. (10,23,24)
This is why specialist-guided interpretation matters, why test results are often reviewed in the context of the whole clinical picture, and why borderline or unexpected results are commonly repeated rather than acted on immediately.
One more concept worth knowing: pre-test probability. The value of any test depends heavily on how likely the condition was before testing began. A positive screen in someone with a strong clinical picture means something different than the same positive screen in someone with no suggestive features. This is why testing is targeted rather than universal — broad screening of low-probability populations generates mostly false positives that lead to unnecessary further testing and anxiety.
Specialist Referral: Who and When
- Sleep medicine — suspected sleep apnea or resistant hypertension with sleep-related features
- Endocrinology — primary aldosteronism, pheochromocytoma, Cushing syndrome, thyroid or parathyroid issues
- Nephrology — CKD, resistant hypertension with kidney involvement
- Vascular / interventional teams — selected renovascular disease cases
- Adult congenital heart disease cardiology — suspected or confirmed coarctation
- Hypertension specialist — complex or refractory cases that don’t fit a clear category
A primary care clinician usually starts the workup and refers when specialty input becomes valuable. There is no rule that secondary hypertension evaluation must happen at a specialty center for everyone — but some causes genuinely require it.
Questions to Discuss with Your Clinician
These are designed to help your conversation, not replace it:
- Does my blood pressure pattern (age of onset, severity, response to medication) fit what we’d expect from primary hypertension, or are there features that suggest a secondary cause?
- Have we ruled out the things that can look like resistant hypertension but aren’t — measurement issues, adherence, white-coat effect, NSAIDs, other interfering substances?
- Given current guidance, should I be screened for primary aldosteronism?
- Are there features that suggest sleep apnea evaluation would be useful?
- Have we reviewed every medication, over-the-counter product, and supplement I take?
- If I were referred to a specialist, who would that be and what would they look for?
What This Means
Most evaluations for secondary hypertension don’t reveal a single reversible cause — and that result is still useful, because it narrows the diagnostic framework and helps focus treatment.
When a secondary driver is found, identifying and treating it can transform management. Sleep apnea treatment, removing an aldosterone-producing nodule, stopping an offending medication, or treating a hormone-producing tumor can change blood pressure control in ways that no amount of medication titration would achieve. In some cases, the cardiovascular risk reduction goes beyond the blood pressure number itself — particularly for primary aldosteronism, where targeted treatment reduces stroke, heart failure, and arrhythmia risk independently of blood pressure control.
The point of secondary hypertension evaluation isn’t exhaustive testing for rare disease. It’s recognizing when the blood pressure pattern doesn’t fit ordinary primary hypertension and following that signal carefully. Sometimes the most important step is not adding another medication, but stepping back and asking whether the physiology itself is pointing toward a different diagnosis.
Article 6 covers lifestyle interventions in depth — the evidence behind dietary patterns, exercise, weight management, alcohol, sleep, and stress reduction as treatments for blood pressure.
Key Terms
Primary (essential) hypertension: High blood pressure that comes from the combined effect of genetics, aging, environment, and lifestyle — without a single identifiable underlying cause. The majority of cases.
Secondary hypertension: High blood pressure that is being driven primarily by an identifiable, often treatable condition (sleep apnea, primary aldosteronism, kidney disease, hormone-producing tumor, medication effect, others).
Resistant hypertension: Blood pressure that stays uncontrolled despite three or more blood pressure medications of different classes, including a diuretic, taken at appropriate doses. Often warrants a search for a secondary cause — but pseudoresistance (measurement issues, adherence, interfering substances) should be ruled out first.
Apparent (pseudo-)resistant hypertension: Blood pressure that looks resistant but isn’t — caused by measurement problems, non-adherence, white-coat effect, very high salt intake, or interfering medications and substances.
Primary aldosteronism (PA): A condition in which the adrenal glands produce too much aldosterone, causing the kidneys to retain salt and water. The most common endocrine cause of secondary hypertension. Often missed because potassium is frequently normal.
Aldosterone-to-renin ratio (ARR): The standard screening test for PA. Measures the relative amounts of two hormones; interpretation is sensitive to medications and conditions, so results are read in clinical context.
Pheochromocytoma: A rare tumor that produces excess adrenaline-like hormones, classically causing episodes of headache, sweating, palpitations, and blood pressure spikes.
Renovascular disease: Narrowing of an artery feeding a kidney; can cause resistant hypertension and kidney dysfunction. Anatomic narrowing seen on imaging is not always physiologically driving hypertension.
Aortic coarctation: A congenital narrowing of the aorta that causes high blood pressure in the upper body and lower pressure in the legs.
Non-dipping: Failure of blood pressure to drop the normal 10% or more during sleep; linked to higher cardiovascular risk and often a clue to sleep apnea or autonomic dysregulation.
References
- Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J.2014;35(19):1245–1254.
- Charles L, Triscott J, Dobbs B. Secondary hypertension: discovering the underlying cause. Am Fam Physician.2017;96(7):453–461.
- Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243–1248.
- Monticone S, D’Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41–50.
- Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53–e90.
- Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. Circulation.2008;117(25):e510–e526.
- Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58(5):811–817.
- Monticone S, Burrello J, Tizzani D, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69(14):1811–1820.
- Adler GK, Stowasser M, Correa RR, et al. Primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2025;110(9):2453–2495.
- Lenders JWM, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–1942.
- Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1–S87.
- Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease. Circulation. 2019;139(14):e698–e800.
- Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19(12):2271–2277.
- Montesi SB, Edwards BA, Malhotra A, Bakker JP. The effect of continuous positive airway pressure treatment on blood pressure: a systematic review and meta-analysis of randomized controlled trials. J Clin Sleep Med.2012;8(5):587–596.
- McEvoy RD, Antic NA, Heeley E, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016;375(10):919–931.
- McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912–4018.
- Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension.2025;82(10):e212–e316. (Co-published in J Am Coll Cardiol 2025;86(18):1567–1678 and Circulation2025;152:e114–e218.)
- Jędrusik P, Symonides B, Lewandowski J, Gaciong Z. The effect of antihypertensive medications on testing for primary aldosteronism. J Hypertens. 2021;39(1):11–21.
- Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5(9):689–699.
- Cheung AK, Chang TI, Cushman WC, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3):559–569.
- Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370(1):13–22.
- Bhalla V, Textor SC, Beckman JA, et al. Revascularization for renovascular disease: a scientific statement from the American Heart Association. Hypertension. 2022;79(8):e128–e143.
- Eisenhofer G, Därr R, Pamporaki C, et al. Pheochromocytoma diagnosis: pitfalls in current sampling and pre-analytical practices. Clin Endocrinol (Oxf). 2015;82(6):789–795.
- Griffin TP, Blake L, Griffin DG, et al. Optimal rest period for plasma metanephrine sampling. Clin Endocrinol (Oxf). 2016;85(4):541–548.
HeartBuddi • Your heart. Own it.